Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update
MINNEAPOLIS , April 01, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to Women’s Oncology, announced today financial results for the quarter and fiscal year ended December 31, 2018 and
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.2 Million of Units
MINNEAPOLIS , March 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
MINNEAPOLIS , March 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be
View HTML
Toggle Summary Precision Therapeutics Announces Results of Special Meeting of Stockholders
MINNEAPOLIS , March 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (the “Company”) announced today that at a special meeting of stockholders held on March 22, 2019 , the Company’s stockholders approved the Amended and Restated Agreement and Plan of Merger, dated as of
View HTML
Toggle Summary Precision Therapeutics to Report Fiscal Year 2018 Financial Results and Provide Company Update on Monday, April 1, 2019
Conference Call to be held April 1, 2019, at 4:30pm Eastern Time MINNEAPOLIS , March 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report Fiscal Year 2018 financial results for the period ended December 31, 2018 ,
View HTML
Toggle Summary Precision Therapeutics Extends Exchange Offer for Helomics Notes and Warrants
MINNEAPOLIS , March 14, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the extension of its previously announced offer (the “Exchange Offer”) to holders of certain promissory notes (the “Helomics Notes Payable”) of Helomics Holding
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Captures Market Share in Saudi Arabia Via New Orders While Disposable Sales Show Significant Year-Over-Year Increase
Company Concluded 2018 With 38 Percent Increase in STREAMWAY System Disposables MINNEAPOLIS , March 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, has entered the African continent, further
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.26 Million of Units
MINNEAPOLIS , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to $1.26
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
MINNEAPOLIS , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no
View HTML
Toggle Summary Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer
MINNEAPOLIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business
View HTML